Margriet Kwint

General discussion and future perspectives 167 8 42. Curran WJ, Jr., Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011;103(19):1452-60. 43. Senan S, Brade A, Wang LH, Vansteenkiste J, Dakhil S, Biesma B, et al. PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2016;34(9):953-62. 44. Bral S, De Ridder M, Duchateau M, Gevaert T, Engels B, Schallier D, et al. Daily megavoltage computed tomography in lung cancer radiotherapy: correlation between volumetric changes and local outcome. Int J Radiat Oncol Biol Phys. 2011;80(5):1338-42. 45. Jabbour SK, Kim S, Haider SA, Xu X, Wu A, Surakanti S, et al. Reduction in Tumor Volume by Cone Beam Computed Tomography Predicts Overall Survival in Non-Small Cell Lung Cancer Treated With Chemoradiation Therapy. Int J Radiat Oncol Biol Phys. 2015;92(3):627-33. 46. Wald P, Mo X, Barney C, Gunderson D, Haglund AK, Bazan J, et al. Prognostic Value of Primary Tumor Volume Changes on kV-CBCT during Definitive Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer. J Thorac Oncol. 2017;12(12):1779-87. 47. Amugongo LM, Vasquez Osorio E, Green AF, Cobben D, van Herk M, McWilliam A. Identification of patterns of tumour change measured on CBCT images in NSCLC patients during radiotherapy. Phys Med Biol. 2020. 48. O’Rourke N, Roque IFM, Farre Bernado N, Macbeth F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev. 2010(6):CD002140. 49. Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv1-iv21. 50. Choy H, LaPorte K, Knill-Selby E, Mohr P, Shyr Y. Esophagitis in combined modality therapy for locally advanced non-small cell lung cancer. Semin Radiat Oncol. 1999;9(2 Suppl 1):90- 6. 51. Wijsman R, Dankers F, Troost EGC, Hoffmann AL, van der Heijden E, de Geus-Oei LF, et al. Comparison of toxicity and outcome in advanced stage non-small cell lung cancer patients treated with intensity-modulated (chemo-)radiotherapy using IMRT or VMAT. Radiother Oncol. 2017;122(2):295-9. 52. Zhang J, Yu XL, Zheng GF, Zhao F. Intensity-modulated radiotherapy and volumetric- modulated arc therapy have distinct clinical advantages in non-small cell lung cancer treatment. Med Oncol. 2015;32(4):94. 53. Akbarov A, Williams R, Brown B, Mamas M, Peek N, Buchan I, et al. A Two-stage Dynamic Model to Enable Updating of Clinical Risk Prediction from Longitudinal Health Record Data: Illustrated with Kidney Function. Stud Health Technol Inform. 2015;216:696-700. 54. Tamblyn R, Girard N, Dixon WG, Haas J, Bates DW, Sheppard T, et al. Pharmacosurveillance without borders: electronic health records in different countries can be used to address important methodological issues in estimating the risk of adverse events. J Clin Epidemiol. 2016;77:101-11. 55. Atkinson TM, Li Y, Coffey CW, Sit L, Shaw M, Lavene D, et al. Reliability of adverse symptom event reporting by clinicians. Qual Life Res. 2012;21(7):1159-64.